Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Simone Klog Loose"'
Autor:
Rafael Lima Viana, M.F. Simões, Fernando Augusto Batista Campos, Vladmir Cláudio Cordeiro de Lima, Luciana de Moura Leite, Bruna Raphaeli Silva Mattos, Paula Tavares Guimarães, Noam Pondé, Debora Maciel Santana, Daniella Dias Silva Sá, F. Rocha, Sinara Figueiredo Silva, Erick Figueiredo Saldanha, Solange Moraes Sanches, Marcelle Goldner Cesca, Rafaela Pirolli, Camilla Albina Zanco Fogassa, Monique Celeste Tavares, Simone Klog Loose
Purpose: Recently, phase I studies with novel antibody drug conjugates targeting HER2 suggested benefit in HER2-low patients – defined as immunohistochemistry(IHC) +1 or +2 FISH/ISH non-amplified, with advanced breast cancer(BC). Data on the progno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d98fd26dd52572004e785fb728f0e6d0
https://doi.org/10.21203/rs.3.rs-420934/v1
https://doi.org/10.21203/rs.3.rs-420934/v1
Autor:
Flores Campos, Solange Moraes Sanches, Camilla Albina Zanco Fogassa, E. Saldanha, R. Viana, D. Sá, C. Toledo, Monique Celeste Tavares, F. Rocha, Simone Klog Loose, Sinara Figueiredo Silva, V.C.C. Lima, Noam Pondé, Marcelle Goldner Cesca, P. Guimarães, Luciana de Moura Leite, R. Piroll, M.F. Simões, D. Santana, F. Makdissi
Publikováno v:
Annals of Oncology. 32:S435-S436
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa6eacaad4dfb9bc8079299e77d3d317
https://doi.org/10.1016/j.annonc.2021.08.457
https://doi.org/10.1016/j.annonc.2021.08.457
Autor:
Poliana de Andrade, Marcelle Goldner Cesca, Monique Celeste Tavares, Solange Moraes Sanches, Flores Campos, V.C.C. de Lima, Camilla Albina Zanco Fogassa, Rafaela Pirolli, Simone Klog Loose, Luciana de Moura Leite, F.A. de Oliveira, Bruna Raphaeli Silva Mattos, Sinara Figueiredo Silva
Publikováno v:
Annals of Oncology. 31:S342
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2302148f92186e9f92a3eb95623188b
https://doi.org/10.1016/j.annonc.2020.08.065
https://doi.org/10.1016/j.annonc.2020.08.065
Autor:
José Augusto Rinck, Aldo Lourenço Abbade Dettino, Luciana de Moura Leite, Simone Klog Loose, Stênio de Cássio Zequi, Maria Nirvana Formiga
Publikováno v:
Journal of Clinical Oncology. 37:644-644
644 Background: The introduction of tyrosine kinase inhibitors (TKI) and recently immunotherapy has brought major survival benefits for metastatic renal cancer (mRCC) patients (pts). In Brazil, there is no approved 2nd line treatment for mRCC in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa7ebac06012dc71d4f12a0a3659c382
https://doi.org/10.1200/jco.2019.37.7_suppl.644
https://doi.org/10.1200/jco.2019.37.7_suppl.644